The impact of SB349 is expected to reshape the landscape of state-sponsored healthcare for retirees, particularly by repealing the existing Maryland State Retiree Prescription Drug Coverage Program and related assistance programs. By revoking these benefits for newer retirees, the bill could lead to increased healthcare costs for a segment of retirees who may not have anticipated losing these state-funded benefits. Supporters of this bill argue that it aligns with federal regulations while proponents of the existing benefits fear that it places undue financial burdens on vulnerable groups, especially those who are dependent on medication and require consistent access to prescription drugs.
Summary
Senate Bill 349 aims to revise the prescription drug benefits for retirees in the Maryland State Employee and Retiree Health and Welfare Benefits Program. The bill is introducing provisions that grant certain retirees who began state service before July 1, 2011, continued eligibility for state prescription drug benefits. However, it also stipulates that prescription drug benefits will be eliminated for Medicare-eligible retirees who started their service on or after this date, along with their Medicare-eligible spouses and dependent children. This change marks a significant adjustment to the existing benefits framework intended for state retirees.
Contention
One major point of contention surrounding SB349 is the balance between fiscal responsibility and social welfare. Advocates argue that the state must cut costs in light of federal mandates and financial constraints, while opponents view the elimination of benefits as an erosion of the state's commitment to supporting its retirees. Additionally, there are concerns regarding how this shift could disproportionately affect lower-income retirees, who may already struggle with the costs of living and healthcare. The bill may lead to further discussions on how best to support retirees while managing the state's budget effectively.
Directing The State Employee Benefits Committee And The Secretary Of Human Resources To Engage With Independent Consultants And Other Supply Chain Tactics For Cost Containment Of Prescription Drugs For State Employees And Retirees Insurance Programs.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.